Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality

By M. Morrell, Victoria J. Fraser, Marin Kollef. Antimicrobial Agents and Chemotherapy, 2005

1,330 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Clinical Biochemistry, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/9248aa19162d7f0f267217e868823fac923f234b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. J. Fishman
2. M. Pfaller
3. D. Diekema

In Clinical Biochemistry

1. J. Fishman
2. M. Pfaller
3. C. Deutschman
4. D. Diekema

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. D. Kontoyiannis
5. Georgios Chamilos
6. J. Fishman
7. J. Perfect
8. E. Anaissie

Citations in the corpus

• Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. (2006, background): “Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
• Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department* (2010, methodology): “The second study found that delaying antifungal therapy for 12 hrs after the initial positive fungal culture was drawn was an independent predictor of hospital mortality (6).”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “mortality [14, 17, 18, 236].”
• Global trends in the distribution of Candida species causing candidemia. (2014, background): “The mortality rate is clearly correlated with a delay in the initiation of appropriate antifungal treatment [14,15].”
• Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. (2012, background): “retrospective analyses have demonstrated that early administration of antifungal drug and removal of CVCs in candidemia improve outcome [34, 42, 50–56].”
• Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008, background): “Furthermore, 2 recent retrospective cohort studies demonstrated that the early initiation of effective empirical antifungal therapy within 12 h after the first finding of a blood sample positive for Candida infection is critical for a successful outcome among patients with candidemia [15, 16].”
• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “Inappropriate therapy or delays in initiation of therapy have also been linked to increased mortality [24, 25].”
• Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 (2013, background): “Prompt infusion of antimicrobial agents should also be a priority and may require additional vascular access ports [68, 69].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Early initiation of effective antifungal therapy is critical in the successful treatment of candidemia, as demonstrated by recent data suggesting higher mortality rates among patients with candidemia whose therapy was delayed [77, 78].”
• Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 (2007, background): “However, prompt infusion of antimicrobial agents should also be a priority and may require additional vascular access ports (42, 43).”
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “Third, recent data support that early treatment of fungal infection with a lower burden of organisms reduces the number of treatment failures [103-105].”
• Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. (2013, background): “These considerations are important because delays in antifungal therapy are associated with poor outcomes [12].”
• Epidemiology of Invasive Mycoses in North America (2010, background): “…treatment with an agent to which the organism is resistant, inadequate dose or duration of treatment, or no treatment at all (Armstrong-James 2007; Atkinson et al. 2008; Garey et al. 2006; Garey et al. 2007; Klevay et al. 2008; Morgan et al. 2005a; Morrell et al. 2005; Parkins et al. 2007).”